Kolexia
Nault Jean-Charles Gastro-entérologie
Nault Jean-Charles
Gastro-entérologie
Hôpital Jean Verdier
Bondy, France
437 Activités
2 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome hépatocellulaire Carcinomes Tumeurs du foie Fibrose Adénome hépatocellulaire Cirrhose du foie Adénomes Maladies du foie Récidive tumorale locale

Collaborateurs

Voir plus
Zucman-Rossi Jessica
Zucman-Rossi Jessica
Hôpital Européen Georges Pompidou, Paris, France
Calderaro Julien
Calderaro Julien
Hôpital Henri Mondor, Créteil, France
Carrie Nathalie
Carrie Nathalie
Hôpital Jean Verdier, Bondy, France
Seror Olivier
Seror Olivier
Hôpital Jean Verdier, Bondy, France

Industries

Voir plus
Ipsen
3 collaboration(s)
Dernière en 2021
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Long-term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma.
Liver international : official journal of the International Association for the Study of the Liver   04 mars 2024
Incidence and clinical impact of bile ducts changes after multibipolar radiofrequency ablation for hepatocellular carcinoma.
European radiology   09 février 2024
No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.
Liver international : official journal of the International Association for the Study of the Liver   30 janvier 2024
Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study: Marqueurs Pronostiques et prédictifs de réponse Aux Traitements Chez Les Patients Atteints de Cancer Des Voies Biliaires : Cohorte Multicentrique ACABi PRONOBIL
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   03 janvier 2024
Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
United European gastroenterology journal   07 décembre 2023
A personalized approach for tumour biopsy in hepatocellular carcinoma
JHEP reports : innovation in hepatology   03 décembre 2023
PET-HCC01: Prospective Study Evaluating the Combination of Positron Emission Tomography (PET) With 18F-FDG and 18 F-Fluorocholine for Optimization of Staging and Treatment Modification in Patients With Hepatocellular Carcinoma
Essai Clinique (Assistance publique – Hôpitaux de Paris)   15 novembre 2023
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
The Lancet. Oncology   08 novembre 2023
Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab.
Hepatology (Baltimore, Md.)   23 octobre 2023
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC.
Clinics and research in hepatology and gastroenterology   02 septembre 2023